Kiadis Pharma's Extraordinary General Meeting of Shareholders Approves CytoSen Acquisition
29 Maio 2019 - 7:05AM
Amsterdam, The
Netherlands, May 29, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or
the "Company") (Euronext Amsterdam and Brussels: KDS), a
clinical stage biopharmaceutical company, today announces that at
its Extraordinary General Meeting of shareholders held today at
10:00 CEST at the Amsterdam Stock Exchange (Euronext), Beursplein
5, 1012 JW Amsterdam, The Netherlands, the resolution to approve
the acquisition of CytoSen Therapeutics, Inc. - the sole proposal
on the agenda - was duly passed by the shareholders.
Arthur Lahr, CEO of Kiadis Pharma,
commented: "We are pleased with the continued support of our
shareholders as demonstrated through their approval of the
acquisition of CytoSen that we obtained at our extraordinary
general meeting of shareholders this morning. With the approval of
the CytoSen acquisition now obtained, we will work to close the
transaction in early June."
For more information, please
contact:
Kiadis Pharma:
Amy Sullivan, SVP, Corporate Affairs
Tel. +1 508 479 3480
a.sullivan@kiadis.com |
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com |
About Kiadis
Pharma
Founded in 1997, Kiadis Pharma, is a fully integrated
biopharmaceutical company committed to developing innovative
therapies for patients with late-stage blood cancers. With
headquarters in Amsterdam, the Netherlands, Kiadis Pharma is
reimagining medicine by leveraging the natural strengths of
humanity and our collective immune system to source the best cells
for life.
Kiadis Pharma is listed on the
regulated market of Euronext Amsterdam and Euronext Brussels since
July 2, 2015, under the symbol KDS. Learn more at kiadis.com.
Forward Looking
Statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma's
or, as appropriate, Kiadis Pharma's directors' current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, competition and technology, can
cause actual events, performance or results to differ significantly
from any anticipated development. Forward looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis Pharma
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in
events, conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis Pharma nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person's officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Kiadis Pharma N. V. via Globenewswire